Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian markets open in green
Fri, 14 Oct 09:30 am

Most major Asian stock markets have opened the day in the red. Stock markets in Hong Kong (down 1.2%) and China (down 1.1%) are leading the losses. However, the Indian stock market have opened the day on a positive note. Consumer durables and healthcare stocks are leading the gains. However, realty and metal stocks are trading in the red.

The BSE-Sensex is trading higher by around 40 points (0.2%), while the NSE-Nifty is up by around 10 points (0.2%). Mid and small cap stocks have opened on a positive note as well with BSE Mid Cap and BSE Small Cap indices up by 0.3% each. The rupee is trading at 49.19 to the US dollar.

Pharma stocks have opened the day on a firm note with Sun Pharma, Orchid Chemicals and Cipla trading firmly in the green. Indian pharmaceutical major Lupin announced that it has launched the generic version of Watson's Fortamet which has annual sales of around US$ 90 m. The branded product's generic name is metformin ER. It is used to improve glycemic control in adults with type II diabetes which is usually related to lifestyle. Lupin has launched the drug despite an impending patent suit against it in the US. It has a first-to-file status on its application with the US Food and Drug Administration (FDA) for the drug. This means that the company would have an exclusive period to sell the drug for 180 days after the litigation is settled.

Sintex Industries has announced the second quarter results for the financial year 2011-2012 (2QFY12). The company has reported around 25.3% year-on-year (YoY) growth in sales. However, operating margins contract to 17.7% during 2QFY12, from 18.6% in 2QFY11. At the bottomline level, net profits have declined by 61.2% YoY. Growth was driven by both the plastics and textiles business divisions, registering a growth of 25.9% YoY and 20.2% YoU respectively. The decline in net profits was due to huge unrealised forex losses. However, adjusting for the forex losses on outstanding FCCBs (foreign currency convertible bonds), net profits increased 23.3% YoY. Even the interest costs were higher during the quarter with the overall working capital cycle increasing due to delayed payments from overseas subsidiaries. The order book in the monolithic segment stands at Rs 30 bn. The stock of Sintex Industries is currently trading marginally in the red.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian markets open in green". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.